v3.26.1
Significant Agreements (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Feb. 01, 2023
Jul. 14, 2022
Jul. 13, 2021
Oct. 31, 2017
Sep. 30, 2018
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Sep. 30, 2021
Feb. 28, 2023
Aug. 31, 2022
Significant Agreements [Line Items]                            
Agreement due payments       $ 1,650                    
Second clinical trial payment       $ 50,000                    
Net sales percentage       2.00%                    
Common stock valued           $ 14,439 $ 19,569 $ 9,538 $ 2,707          
Anti-dilution shares of common stock (in Shares)           19,624,727   18,833,095   19,624,727 18,833,095      
Milestone payments $ 3,700                          
Lotus International Pte Ltd [Member]                            
Significant Agreements [Line Items]                            
Sublicense income percentage                   20.00%        
Lee’s Pharmaceutical (HK) Limited [Member]                            
Significant Agreements [Line Items]                            
Significant payment received   $ 1,000                        
Milestone payments   $ 1,000                        
Lotus International Pte Ltd [Member]                            
Significant Agreements [Line Items]                            
Significant payment received $ 700                          
Shilpa Medicare Ltd [Member]                            
Significant Agreements [Line Items]                            
Payment amount                   $ 4,500        
Exclusive license agreement [Member]                            
Significant Agreements [Line Items]                            
Agreement due payments       $ 50,000                    
Spectrum Agreement [Member]                            
Significant Agreements [Line Items]                            
Issued of common shares (in Shares)         31,366                  
Common stock valued         $ 4,000                  
Public market capitalization     $ 50,000   $ 50,000                  
Research and development expenses                       $ 2,200    
Sublicense income granted percentage                       40.00%    
Sublicense income percentage                       20.00%    
Spectrum Agreement [Member] | Common Stock [Member]                            
Significant Agreements [Line Items]                            
Anti-dilution shares of common stock (in Shares)     43,838                      
Spectrum Agreement [Member] | Investment [Member]                            
Significant Agreements [Line Items]                            
Interest on ownership         4.00%                  
Spectrum Agreement [Member] | Altair Nanomaterials, Inc [Member]                            
Significant Agreements [Line Items]                            
Required to pay                       $ 200    
Spectrum Agreement [Member] | Altair [Member]                            
Significant Agreements [Line Items]                            
Required to pay                       $ 4,500    
Sublicense Development Agreement [Member]                            
Significant Agreements [Line Items]                            
Significant payment received                         $ 700 $ 1,000
Minimum [Member]                            
Significant Agreements [Line Items]                            
Royalties percentage   7.00%                        
Maximum [Member]                            
Significant Agreements [Line Items]                            
Royalties percentage   10.00%